243 related articles for article (PubMed ID: 32912383)
21. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
22. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis.
Li J; Yang G; Cai Q; Wang Y; Xu Y; Zhang R; Lang Y; Cai X
Int J Infect Dis; 2021 Sep; 110():179-186. PubMed ID: 34293490
[TBL] [Abstract][Full Text] [Related]
23. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J;
Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286
[TBL] [Abstract][Full Text] [Related]
24. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States.
Mase S; Chorba T; Parks S; Belanger A; Dworkin F; Seaworth B; Warkentin J; Barry P; Shah N
Clin Infect Dis; 2020 Aug; 71(4):1010-1016. PubMed ID: 31556947
[TBL] [Abstract][Full Text] [Related]
25. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
[TBL] [Abstract][Full Text] [Related]
26. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
[TBL] [Abstract][Full Text] [Related]
27. Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia.
Hewison C; Bastard M; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Kiria N; Yegiazaryan L; Chumburidze N; Kirakosyan O; Atshemyan H; Qayyum S; Lachenal N; Varaine F; Huerga H
Int J Tuberc Lung Dis; 2018 Jul; 22(7):766-772. PubMed ID: 29914602
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
[TBL] [Abstract][Full Text] [Related]
29. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
[TBL] [Abstract][Full Text] [Related]
30. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
Fekadu G; Yao J; You JHS
PLoS One; 2022; 17(8):e0272770. PubMed ID: 35930574
[TBL] [Abstract][Full Text] [Related]
31. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
[TBL] [Abstract][Full Text] [Related]
32. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China.
Wu HY; Tian Y; Wang XD; Sun JS; Fan LC; Chen MX; Li R; Chen Y
J Paediatr Child Health; 2022 Jan; 58(1):116-121. PubMed ID: 34323328
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Solodovnikova V; Kumar AMV; Hurevich H; Sereda Y; Auchynka V; Katovich D; Klimuk D; Skrahin A; Setkina S; Charnysh I; Yedilbayev A; Skrahina A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470080
[TBL] [Abstract][Full Text] [Related]
34. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
[TBL] [Abstract][Full Text] [Related]
35. Bedaquiline: Current status and future perspectives.
Khoshnood S; Goudarzi M; Taki E; Darbandi A; Kouhsari E; Heidary M; Motahar M; Moradi M; Bazyar H
J Glob Antimicrob Resist; 2021 Jun; 25():48-59. PubMed ID: 33684606
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
Guglielmetti L; Jaspard M; Le Dû D; Lachâtre M; Marigot-Outtandy D; Bernard C; Veziris N; Robert J; Yazdanpanah Y; Caumes E; Fréchet-Jachym M;
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182570
[TBL] [Abstract][Full Text] [Related]
37. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
38. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data.
Darmayani IGAAPS; Ascobat P; Instiaty I; Sugiri YJR; Sawitri N
Acta Med Indones; 2022 Jul; 54(3):389-396. PubMed ID: 36156479
[TBL] [Abstract][Full Text] [Related]
39. [Progress on the safety and efficacy of bedaquiline for the treatment of drug-resistant tuberculosis in special populations].
Zhang YP; Niu YY; Tang PJ
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Jun; 46(6):619-624. PubMed ID: 37278180
[TBL] [Abstract][Full Text] [Related]
40. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]